The Johns Hopkins Comprehensive Cancer Center is dedicated to research in education and cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. The Johns Hopkins Comprehensive Cancer Center is a multi-disciplinary, interdepartmental center of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The specific scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity of encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new anti-tumor treatments. The Cancer Center research into the molecular genetics of human tumorigenesis to clinical trials of new anti-tumor treatments. The Cancer Center has established seven major research programs: Cancer Biology, Experimental and Therapeutic Hematopoiesis, Experimental Therapeutics/Solid Tumor Research, Cancer Immunology, Viral Oncology, Cancer Prevention and Control, and Urologic Oncology. Fifteen Shared Resources support the needs of Cancer Center investigators: Cell Sorting and Imaging Core, Animal Resources, Vector Core, Experimental Irradiators, Glassware Washing, Common Equipment, Molecular Pathology Core/Hematologic Malignancy Cell Procurement, Cytogenetics and Molecular Genetics, Pharmacology Analytic, Hematopoietic and Therapeutic Support, Cell and Gene Therapy, Research Pharmacy, Biostatistics, and Clinical Research Office. Interdisciplinary research seminars and research training programs provide valuable opportunities for interdisciplinary interaction and collaboration. Cancer Center developmental founds are used to support faculty recruitment and innovative research; development of shared resources; and a small allocation to pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006973-42S1
Application #
6937431
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
2004-08-16
Budget End
2005-04-30
Support Year
42
Fiscal Year
2004
Total Cost
$248,577
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications